

# **Global Flow Cytometry in Oncology Market: Focus on Product Type, Technology, Type of Cancer, Applications, End Users, Country Data (16 Countries), and Competitive Landscape - Analysis and Forecast, 2021-2031**

<https://marketpublishers.com/r/G13A9AFD9C5EEN.html>

Date: June 2021

Pages: 257

Price: US\$ 5,250.00 (Single User License)

ID: G13A9AFD9C5EEN

## **Abstracts**

Market Report Coverage - Flow Cytometry in Oncology

Market Segmentation

Product Type – Assays and Kits, Instruments, Reagents and Consumables, and Software

Technology – Cell-Based and Bead-Based

Type of Cancer – Hematological Malignancies (Lymphoma, Leukemia, Myeloma, and Other Hematological Malignancies) and Solid Tumors (Breast Cancer, Prostate Cancer, Colorectal Cancer, Lung Cancer, and Other Solid Tumors)

Application – Translational Research and Clinical Applications (Screening and Diagnostics, and Treatment Monitoring)

End User – Diagnostic Laboratories, Hospitals and Healthcare Centers, Academic and Research Institutions, and Other End Users

Regional Segmentation

North America – U.S., and Canada

Europe – Germany, U.K., France, Italy, Spain, Netherlands, and Rest-of-Europe

Asia-Pacific – China, Japan, India, Australia, South Korea, Singapore, and Rest-of-Asia-Pacific

Latin America – Brazil, Mexico, and Rest-of-Latin America

Rest-of-the-World

### Market Growth Drivers

Rising Incidence of Hematological Malignancies

Increasing Fund Infusions for Hematological Malignancies

Growing Consumer Awareness for Tailored Therapy and Precision Medicine

### Market Challenges

False Negatives and Positives

Restricted Specificity Offered by Conventional Flow Cytometry-Based MRD Assessment

### Market Opportunities

Technological Evolution in the Field of Flow Cytometry

Growth in Solid Tumor Applications of Flow Cytometry

### Key Surgical Instrument Tracking Devices Companies Profiled

Agilent Technologies, Inc., Apogee Flow Systems Ltd., Becton, Dickinson and

*Global Flow Cytometry in Oncology Market: Focus on Product Type, Technology, Type of Cancer, Applications, End...*

Company, bioAffinity Technologies, Inc., Bio-Rad Laboratories, Inc., Bio-Techne Corporation, Cytex Biosciences, Cytognos, S.L., Danaher Corporation, Miltenyi Biotec B.V. & Co. KG, Laboratory Corporation of America Holdings, Luminex Corporation, NeoGenomics Laboratories, Inc., Sony Corporation, and Thermo Fisher Scientific Inc.

Key Questions Answered in this Report:

How is flow cytometry revolutionizing the field of oncology?

What are the major market drivers, challenges, and opportunities in the global flow cytometry in oncology market?

What are the underlying structures resulting in the emerging trends within the global flow cytometry in oncology market?

How is the COVID-19 pandemic impacting the global flow cytometry in oncology ecosystem?

What are the key development strategies that are being implemented by the major players in order to sustain the competitive market?

What are the key regulatory implications in developed and developing regions pertaining to the use of flow cytometry in the field of oncology?

What are the potential entry barriers expected to be faced by the companies willing to enter a particular region?

How is each segment of the market expected to grow during the forecast period 2021-2031, and what is the anticipated revenue to be generated by each of the segments? Following are the segments:

Product Type (assays and kits, instruments, reagents and consumables, and software)

Technology (cell-based and bead-based)

Type of Cancer (hematological malignancies and solid tumor)

Application (translational research and clinical applications)

End User (diagnostic laboratories, hospitals and healthcare clinics, academic and research institutions, and other end users)

Region (North America, Europe, Asia-Pacific, Latin America, and Rest-of-the-World)

What are the growth opportunities for the companies in the region of their operation?

Who are the leading players with significant offerings in the global flow cytometry in oncology market?

Which companies are anticipated to be highly disruptive in the future, and why?

## Market Overview

Our healthcare experts have found flow cytometry in oncology industry to be one of the most rapidly evolving and dynamic markets. The global market for flow cytometry in oncology is predicted to grow at a CAGR of 12.02% over the forecast period 2021-2031. The market is driven by certain factors, including rising incidence of hematological malignancies, increasing fund infusions for hematological malignancies, and growing consumer awareness for tailored therapy and precision medicine.

The market is favored by the developments in the field of cancer diagnostic testing and its attributes such as flow cytometry. Currently, the flow cytometry in oncology industry is witnessing an upsurge due to the rising incidence of hematological malignancies, increasing fund infusions for hematological malignancies, and growing consumer awareness for tailored therapy and precision medicine. Additionally, high adoption of flow cytometry instruments by the end users to conduct cancer diagnosis and therapeutic monitoring are some of the critical factors that are expected to bolster the market growth.

Furthermore, biotechnology companies are focusing on the development of robust flow cytometry solutions for a wide range of applications, including translational research and clinical applications, to support researchers and physicians in unraveling insights pertaining to cellular alterations.

Within the research report, the market is segmented on the basis of product type, technology, type of cancer, application, end users, and region. Each of these segments covers the snapshot of the market over the projected years, the inclination of the market revenue, underlying patterns, and trends by using analytics on the primary and secondary data obtained.

### Competitive Landscape

The exponential rise in the number of cases associated with cancer, particularly hematological malignancies, has created a buzz among the biotechnology companies to further invest in the development of cancer diagnostic solutions such as flow cytometry, further aiding physicians to offer value-based therapeutic outcomes to patients. Becton, Dickinson and Company has been a pioneer in this field and has been a significant competitor in this market due to the presence of a diverse product portfolio and intense market penetration.

On the basis of region, in 2020, North America held the largest share of the flow cytometry in oncology market due to high infusion of funding from the government organizations for conducting cancer research, growing incidence and prevalence of cancer, growing awareness about precision medicine, and increasing awareness about early cancer detection, among others. Apart from this, the Asia-Pacific region is anticipated to grow at the fastest CAGR during the forecast period 2021-2031.

## Contents

### EXECUTIVE SUMMARY

### 1 PRODUCT DEFINITION

#### 1.1 Inclusion and Exclusion

### 2 MARKET SCOPE

#### 2.1 Scope of the Study

#### 2.2 Key Questions Answered in the Report

### 3 RESEARCH METHODOLOGY

#### 3.1 Global Flow Cytometry in Oncology Market: Research Methodology

#### 3.2 Data Sources

##### 3.2.1 Primary Data Sources

##### 3.2.2 Secondary Data Sources

#### 3.3 Market Estimation Model

#### 3.4 Criteria for Company Profiling

### 4 MARKET OVERVIEW

#### 4.1 Market Definition

#### 4.2 Application of Flow Cytometry in Oncology (Hematological vs. Solid Tumors)

#### 4.3 Market Footprint and Growth Potential

#### 4.4 COVID-19 Impact: Global Flow Cytometry in Oncology Market

### 5 INDUSTRY INSIGHTS

#### 5.1 Overview

#### 5.2 Legal Requirements and Framework in U.S.

#### 5.3 Legal Requirements and Framework in Europe

#### 5.4 Legal Requirements and Framework in Asia-Pacific

##### 5.4.1 China

##### 5.4.2 Japan

### 6 MARKET DYNAMICS

## 6.1 Overview

## 6.2 Impact Analysis

## 6.3 Market Drivers

### 6.3.1 Rising Incidence of Hematological Malignancies

### 6.3.2 Increasing Fund Infusions for Hematological Malignancies

### 6.3.3 Growing Consumer Awareness for Tailored Therapy and Precision Medicine

## 6.4 Market Restraints

### 6.4.1 False Negatives and Positives

### 6.4.2 Restricted Specificity Offered by Conventional Flow Cytometry-Based MRD

## Assessment

## 6.5 Market Opportunities

### 6.5.1 Technological Evolution in the Field of Flow Cytometry

#### 6.5.1.1 Emergence of Multiparametric Flow Cytometry for Hematologic Malignancies

#### 6.5.1.2 Growing Focus on Next-Generation Flow Cytometry

### 6.5.2 Growth in Solid Tumor Applications of Flow Cytometry

## **7 COMPETITIVE LANDSCAPE**

## 7.1 Product Launches

## 7.2 Synergistic Activities

## 7.3 Acquisitions

## 7.4 Product Approvals and Business Expansion Activities

## 7.5 Market Share Analysis, 2019–2020

## 7.6 Growth Share Analysis

### 7.6.1 Growth Share Analysis (by Company)

### 7.6.2 Growth Share Analysis (by Technology)

### 7.6.3 Growth Share Analysis (by Type of Cancer)

### 7.6.4 Growth Share Analysis (by Application)

## 7.7 Competitive Assessment of Different Technologies Utilized for MRD Testing

## **8 GLOBAL FLOW CYTOMETRY IN ONCOLOGY MARKET (BY PRODUCT TYPE), \$MILLION, 2020-2031**

## 8.1 Overview

## 8.2 Assays and Kits

## 8.3 Instruments

## 8.4 Reagents and Consumables

## 8.5 Software

## **9 GLOBAL FLOW CYTOMETRY IN ONCOLOGY MARKET (BY TECHNOLOGY), \$MILLION, 2020-2031**

- 9.1 Overview
- 9.2 Cell-Based
- 9.3 Bead-Based

## **10 GLOBAL FLOW CYTOMETRY IN ONCOLOGY MARKET (BY TYPE OF CANCER), \$MILLION, 2020-2031**

- 10.1 Overview
- 10.2 Hematological Malignancies
  - 10.2.1 Lymphoma
  - 10.2.2 Leukemia
  - 10.2.3 Myeloma
  - 10.2.4 Other Hematological Malignancies
  - 10.2.5 Global Flow Cytometry Market for Hematological Malignancies (by Technology)
- 10.3 Solid Tumors
  - 10.3.1 Breast Cancer
  - 10.3.2 Prostate Cancer
  - 10.3.3 Colorectal Cancer (CRC)
  - 10.3.4 Lung Cancer
  - 10.3.5 Other Solid Tumors
  - 10.3.6 Global Flow Cytometry in Oncology Market for Solid Tumors (by Technology)

## **11 GLOBAL FLOW CYTOMETRY IN ONCOLOGY MARKET (BY APPLICATION), \$MILLION, 2020-2031**

- 11.1 Overview
- 11.2 Translational Research
- 11.3 Clinical Applications
  - 11.3.1 Screening and Diagnostics
  - 11.3.2 Treatment Monitoring

## **12 GLOBAL FLOW CYTOMETRY IN ONCOLOGY MARKET (BY END USER), \$MILLION, 2020-2031**

- 12.1 Overview



- 12.2 Diagnostic Laboratories
- 12.3 Hospitals and Healthcare Clinics
- 12.4 Academic and Research Institutions
- 12.5 Other End Users

## **13 GLOBAL FLOW CYTOMETRY IN ONCOLOGY MARKET (BY REGION), \$MILLION, 2020-2031**

- 13.1 Overview
- 13.2 North America
  - 13.2.1 U.S.
  - 13.2.2 Canada
  - 13.2.3 North America Flow Cytometry in Oncology Market (by Type of Cancer)
- 13.3 Europe
  - 13.3.1 Germany
  - 13.3.2 U.K.
  - 13.3.3 France
  - 13.3.4 Italy
  - 13.3.5 Spain
  - 13.3.6 Netherlands
  - 13.3.7 Rest-of-Europe
  - 13.3.8 Europe Flow Cytometry in Oncology Market (by Type of Cancer)
- 13.4 Asia-Pacific (APAC)
  - 13.4.1 China
  - 13.4.2 Japan
  - 13.4.3 India
  - 13.4.4 Australia
  - 13.4.5 South Korea
  - 13.4.6 Singapore
  - 13.4.7 Rest-of-Asia-Pacific (RoAPAC)
  - 13.4.8 Asia-Pacific Flow Cytometry in Oncology Market (by Type of Cancer)
- 13.5 Latin America (LATAM0)
  - 13.5.1 Brazil
  - 13.5.2 Mexico
  - 13.5.3 Rest-of-Latin America (RoLA)
  - 13.5.4 Latin America Flow Cytometry in Oncology Market (by Type of Cancer)
- 13.6 Rest-of-the-World (RoW)
  - 13.6.1 Rest-of-the-World Flow Cytometry in Oncology Market (by Type of Cancer)

## 14 COMPANY PROFILES

### 14.1 Overview

#### 14.2 Agilent Technologies, Inc.

##### 14.2.1 Company Overview

##### 14.2.2 Role of Agilent Technologies, Inc. in the Global Flow Cytometry in Oncology Market

##### 14.2.3 Financials

##### 14.2.4 Key Insights About Financial Health of the Company

##### 14.2.5 SWOT Analysis

#### 14.3 Apogee Flow Systems Ltd.

##### 14.3.1 Company Overview

##### 14.3.2 Role of Apogee Flow Systems Ltd. in the Global Flow Cytometry in Oncology Market

##### 14.3.3 SWOT Analysis

#### 14.4 Becton, Dickinson and Company

##### 14.4.1 Company Overview

##### 14.4.2 Role of Becton, Dickinson and Company in the Global Flow Cytometry in Oncology Market

##### 14.4.3 Financials

##### 14.4.4 Key Insights About Financial Health of the Company

##### 14.4.5 SWOT Analysis

#### 14.5 bioAffinity Technologies, Inc.

##### 14.5.1 Company Overview

##### 14.5.2 Role of bioAffinity Technologies, Inc. in the Global Flow Cytometry in Oncology Market

##### 14.5.3 SWOT Analysis

#### 14.6 Bio-Rad Laboratories, Inc.

##### 14.6.1 Company Overview

##### 14.6.2 Role of Bio-Rad Laboratories, Inc. in the Global Flow Cytometry in Oncology Market

##### 14.6.3 Financials

##### 14.6.4 Key Insights About Financial Health of the Company

##### 14.6.5 SWOT Analysis

#### 14.7 Bio-Techne Corporation

##### 14.7.1 Company Overview

##### 14.7.2 Role of Bio-Techne Corporation in the Global Flow Cytometry in Oncology Market

##### 14.7.3 Financials

- 14.7.4 Key Insights About Financial Health of the Company
- 14.7.5 SWOT Analysis
- 14.8 Cytex Biosciences
  - 14.8.1 Company Overview
  - 14.8.2 Role of Cytex Biosciences in the Global Flow Cytometry in Oncology Market
  - 14.8.3 SWOT Analysis
- 14.9 Cytognos, S.L.
  - 14.9.1 Company Overview
  - 14.9.2 Role of Cytognos, S.L. in the Global Flow Cytometry in Oncology Market
  - 14.9.3 SWOT Analysis
- 14.10 Danaher Corporation
  - 14.10.1 Company Overview
  - 14.10.2 Role of Danaher Corporation in the Global Flow Cytometry in Oncology Market
  - 14.10.3 Financials
  - 14.10.4 Key Insights About Financial Health of the Company
  - 14.10.5 SWOT Analysis
- 14.11 Miltenyi Biotec B.V. & Co. KG
  - 14.11.1 Company Overview
  - 14.11.2 Role of Miltenyi Biotec B.V. & Co. KG in the Global Flow Cytometry in Oncology Market
  - 14.11.3 SWOT Analysis
- 14.12 Laboratory Corporation of America Holdings
  - 14.12.1 Company Overview
  - 14.12.2 Role of Laboratory Corporation of America Holdings in the Global Flow Cytometry in Oncology Market
  - 14.12.3 Financials
  - 14.12.4 SWOT Analysis
- 14.13 Luminex Corporation
  - 14.13.1 Company Overview
  - 14.13.2 Role of Luminex Corporation in the Global Flow Cytometry in Oncology Market
  - 14.13.3 Financials
  - 14.13.4 Key Insights About Financial Health of the Company
  - 14.13.5 SWOT Analysis
- 14.14 NeoGenomics Laboratories, Inc.
  - 14.14.1 Company Overview
  - 14.14.2 Role of NeoGenomics Laboratories, Inc. in the Global Flow Cytometry in Oncology Market
  - 14.14.3 Financials
  - 14.14.4 Key Insights about Financial Health of the Company

14.14.5 SWOT Analysis

14.15 Sony Corporation

14.15.1 Company Overview

14.15.2 Role of Sony Corporation in the Global Flow Cytometry in Oncology Market

14.15.3 Financials

14.15.4 Key Insights About Financial Health of the Company

14.15.5 SWOT Analysis

14.16 Thermo Fisher Scientific Inc.

14.16.1 Company Overview

14.16.2 Role of Thermo Fisher Scientific Inc. in the Global Flow Cytometry in Oncology Market

14.16.3 Financials

14.16.4 Key Insights About Financial Health of the Company

14.16.5 SWOT Analysis

## List Of Tables

### LIST OF TABLES

Table 6.1: Likert Scale

Table 6.2: Impact Analysis of Market Drivers

Table 6.3: Impact Analysis of Market Restraints

## List Of Figures

### LIST OF FIGURES

- Figure 1: Prevalence of Hematological Malignancies in the U.S., 2013-2016
- Figure 2: National Cancer Institute (NCI) of the U.S., Fiscal Budget Year-on-Year, 2013-2018
- Figure 3: Impact Analysis of Market Drivers and Market Challenges on Global Flow Cytometry in Oncology Market
- Figure 4: Global Flow Cytometry in Oncology Market (by Product Type), \$Million, 2020 and 2031
- Figure 5: Global Flow Cytometry in Oncology Market (by Technology), \$Million, 2020 and 2031
- Figure 6: Global Flow Cytometry in Oncology Market (by Type of Cancer), \$Million, 2020 and 2031
- Figure 7: Global Flow Cytometry in Oncology Market (by Application), \$Million, 2020 and 2031
- Figure 8: Global Flow Cytometry in Oncology Market (by End User), \$Million, 2020 and 2031
- Figure 9: Global Flow Cytometry in Oncology: Market Snapshot
- Figure 2.1: Market Segmentation of Global Flow Cytometry in Oncology Market
- Figure 3.1: Global Flow Cytometry in Oncology Market: Methodology
- Figure 3.2: Primary Research Methodology
- Figure 3.3: Bottom-Up Approach (Segment-Wise Analysis)
- Figure 3.4: Top-Down Approach (Segment-Wise Analysis)
- Figure 4.1: Global Flow Cytometry in Oncology Market, \$Million, 2020-2031
- Figure 4.2: Global Flow Cytometry in Oncology Market: COVID-19 Impact
- Figure 6.1: Global Incidence and Mortality Rate for Individual Hematological Conditions, 2016
- Figure 6.2: Estimated New Cases of Hematological Cancer, 2020
- Figure 7.1: Share of Key Developments and Strategies, January 2017–May 2021
- Figure 7.2: Number of Product Launches (by Company), January 2017–May 2021
- Figure 7.3: Share of Synergistic Activities (by Company), January 2017-May 2021
- Figure 7.4: Share of Acquisitions (by Company), January 2017–May 2021
- Figure 7.5: Market Share Analysis for Global Flow Cytometry in Oncology Market, \$Million, 2019 and 2020
- Figure 7.6: Growth Share Analysis for Global Flow Cytometry in Oncology Market (by Company), 2020
- Figure 7.7: Growth Share Analysis for Global Flow Cytometry in Oncology Market (by

Technology), 2020-2031

Figure 7.8: Growth Share Analysis for Global Flow Cytometry in Oncology Market (by Type of Cancer), 2020-2031

Figure 7.9: Growth Share Analysis for Global Flow Cytometry in Oncology Market (by Application), 2020-2031

Figure 7.10: Comparative Assessment of Technologies Used in MRD Testing

Figure 8.1: Global Flow Cytometry in Oncology Market (by Product Type)

Figure 8.2: Global Flow Cytometry in Oncology Market (by Product Type), \$Million, 2020 and 2031

Figure 8.3: Global Flow Cytometry in Oncology Market (Assays and Kits), \$Million, 2020-2031

Figure 8.4: Global Flow Cytometry in Oncology Market (Instruments), \$Million, 2020-2031

Figure 8.5: Global Flow Cytometry in Oncology Market (Reagents and Consumables), \$Million, 2020-2031

Figure 8.6: Global Flow Cytometry in Oncology Market (Software), \$Million, 2020-2031

Figure 9.1: Global Flow Cytometry in Oncology Market (by Technology)

Figure 9.2: Global Flow Cytometry in Oncology Market (by Technology), \$Million, 2020 and 2031

Figure 9.3: Global Flow Cytometry in Oncology Market (Cell-Based), \$Million, 2020-2031

Figure 9.4: Global Flow Cytometry in Oncology Market (Bead-Based), \$Million, 2020-2031

Figure 10.1: Global Flow Cytometry in Oncology Market (by Type of Cancer)

Figure 10.2: Global Flow Cytometry in Oncology Market (by Type of Cancer), \$Million, 2020 and 2031

Figure 10.3: Global Flow Cytometry in Oncology Market (by Hematological Malignancies), \$Million, 2020-2031

Figure 10.4: Global Flow Cytometry in Oncology Market (by Hematological Malignancies), \$Million, 2020 and 2031

Figure 10.5: Global Flow Cytometry in Oncology Market (Lymphoma), \$Million, 2020-2031

Figure 10.6: Global Flow Cytometry in Oncology Market (Leukemia), \$Million, 2020-2031

Figure 10.7: Global Flow Cytometry in Oncology Market (Myeloma), \$Million, 2020-2031

Figure 10.8: Global Flow Cytometry in Oncology Market (Other Hematological Malignancies), \$Million, 2020-2031

Figure 10.9: Global Flow Cytometry in Oncology Market for Hematological Malignancies (by Technology), \$Million, 2020-2031

Figure 10.10: Global Flow Cytometry in Oncology Market (by Solid Tumors), \$Million, 2020-2031

Figure 10.11: Global Flow Cytometry in Oncology Market (by Solid Tumors), \$Million, 2020 and 2031

Figure 10.12: Global Flow Cytometry in Oncology Market (Breast Cancer), \$Million, 2020-2031

Figure 10.13: Global Flow Cytometry in Oncology Market (Prostate Cancer), \$Million, 2020-2031

Figure 10.14: Global Flow Cytometry in Oncology Market (Colorectal Cancer), \$Million, 2020-2031

Figure 10.15: Global Flow Cytometry in Oncology Market (Lung Cancer), \$Million, 2020-2031

Figure 10.16: Global Flow Cytometry in Oncology Market (Other Solid Tumors), \$Million, 2020-2031

Figure 10.17: Global Flow Cytometry in Oncology Market for Solid Tumors (by Technology), \$Million, 2020-2031

Figure 11.1: Global Flow Cytometry in Oncology Market (by Application)

Figure 11.2: Global Flow Cytometry in Oncology Market (by Application), \$Million, 2020-2031

Figure 11.3: Global Flow Cytometry in Oncology Market (Translational Research), \$Million, 2020-2031

Figure 11.4: Global Flow Cytometry in Oncology Market (by Clinical Applications), \$Million, 2020 and 2031

Figure 11.5: Global Flow Cytometry in Oncology Market (Screening and Diagnostics), \$Million, 2020-2031

Figure 11.6: Global Flow Cytometry in Oncology Market (Treatment Monitoring), \$Million, 2020-2031

Figure 12.1: Global Flow Cytometry in Oncology Market (by End User)

Figure 12.2: Global Flow Cytometry in Oncology Market (by End User), \$Million, 2020-2031

Figure 12.3: Global Flow Cytometry in Oncology Market (Diagnostic Laboratories), \$Million, 2020-2031

Figure 12.4: Global Flow Cytometry in Oncology Market (Hospitals and Healthcare Clinics), \$Million, 2020-2031

Figure 12.5: Global Flow Cytometry in Oncology Market (Academic and Research Institutions), \$Million, 2020-2031

Figure 12.6: Global Flow Cytometry in Oncology Market (Other End Users), \$Million, 2020-2031

Figure 13.1: Global Flow Cytometry in Oncology Market (by Region)



Figure 13.2: Global Flow Cytometry in Oncology Market (by Region), \$Million, 2020-2031

Figure 13.3: Global Flow Cytometry in Oncology Market (by Region), \$Million, 2020-2031

Figure 13.4: North America Flow Cytometry in Oncology Market, \$Million, 2020-2031

Figure 13.5: North America: Market Dynamics

Figure 13.6: North America Flow Cytometry in Oncology Market (by Country), \$Million, 2020-2031

Figure 13.7: U.S. Flow Cytometry in Oncology Market, \$Million, 2020-2031

Figure 13.8: Canada Flow Cytometry in Oncology Market, \$Million, 2020-2031

Figure 13.9: North America Flow Cytometry in Oncology Market (by Type of Cancer), \$Million, 2020-2031

Figure 13.10: Europe Flow Cytometry in Oncology Market, \$Million, 2020-2031

Figure 13.11: Europe: Market Dynamics

Figure 13.12: Europe Flow Cytometry in Oncology Market (by Country), \$Million, 2020-2031

Figure 13.13: Germany Flow Cytometry in Oncology Market, \$Million, 2020-2031

Figure 13.14: U.K. Flow Cytometry in Oncology Market, \$Million, 2020-2031

Figure 13.15: France Flow Cytometry in Oncology Market, \$Million, 2020-2031

Figure 13.16: Italy Flow Cytometry in Oncology Market, \$Million, 2020-2031

Figure 13.17: Spain Flow Cytometry in Oncology Market, \$Million, 2020-2031

Figure 13.18: Netherlands Flow Cytometry in Oncology Market, \$Million, 2020-2031

Figure 13.19: Rest-of-Europe Flow Cytometry in Oncology Market, \$Million, 2020-2031

Figure 13.20: Europe Flow Cytometry in Oncology Market (by Type of Cancer), \$Million, 2020-2031

Figure 13.21: Asia-Pacific Flow Cytometry in Oncology Market, \$Million, 2020-2031

Figure 13.22: Asia-Pacific: Market Dynamics

Figure 13.23: APAC Flow Cytometry in Oncology Market (by Country), \$Million, 2020-2031

Figure 13.24: China Flow Cytometry in Oncology Market, \$Million, 2020-2031

Figure 13.25: Japan Flow Cytometry in Oncology Market, \$Million, 2020-2031

Figure 13.26: India Flow Cytometry in Oncology Market, \$Million, 2020-2031

Figure 13.27: Australia Flow Cytometry in Oncology Market, \$Million, 2020-2031

Figure 13.28: South Korea Flow Cytometry in Oncology Market, \$Million, 2020-2031

Figure 13.29: Singapore Flow Cytometry in Oncology Market, \$Million, 2020-2031

Figure 13.30: RoAPAC Flow Cytometry in Oncology Market, \$Million, 2020-2031

Figure 13.31: APAC Flow Cytometry in Oncology Market (by Type of Cancer), \$Million, 2020-2031

Figure 13.32: Latin America Flow Cytometry in Oncology Market, \$Million, 2020-2031

Figure 13.33: Latin America: Market Dynamics

Figure 13.34: Latin America Flow Cytometry in Oncology Market (by Country), \$Million, 2020-2031

Figure 13.35: Brazil Flow Cytometry in Oncology Market, \$Million, 2020-2031

Figure 13.36: Mexico Flow Cytometry in Oncology Market, \$Million, 2020-2031

Figure 13.37: RoLA Flow Cytometry in Oncology Market, \$Million, 2020-2031

Figure 13.38: LATAM Flow Cytometry in Oncology Market (by Type of Cancer), \$Million, 2020-2031

Figure 13.39: Rest-of-the-World Flow Cytometry in Oncology Market, \$Million, 2020-2031

Figure 13.40: Rest-of-the-World Flow Cytometry in Oncology Market (by Type of Cancer), \$Million, 2020-2031

Figure 14.1: Total Number of Companies Profiles

Figure 14.2: Agilent Technologies, Inc.: Product Portfolio

Figure 14.3: Agilent Technologies, Inc.: Overall Financials, 2018-2020

Figure 14.4: Agilent Technologies, Inc.: Revenue (by Segment), 2018-2020

Figure 14.5: Agilent Technologies, Inc.: Revenue (by Region), 2018-2020

Figure 14.6: Agilent Technologies, Inc.: R&D Expenditure, 2018-2020

Figure 14.7: Agilent Technologies, Inc.: SWOT Analysis

Figure 14.8: Apogee Flow Systems Ltd.: Product Portfolio

Figure 14.9: Apogee Flow Systems Ltd.: SWOT Analysis

Figure 14.10: Becton, Dickinson and Company: Product Portfolio

Figure 14.11: Becton, Dickinson and Company: Overall Financials, 2018-2020

Figure 14.12: Becton, Dickinson and Company: Revenue (by Segment), 2018-2020

Figure 14.13: Becton, Dickinson and Company: Revenue (by Region), 2018-2020

Figure 14.14: Becton, Dickinson and Company: R&D Expenditure, 2018-2020

Figure 14.15: Becton, Dickinson and Company: SWOT Analysis

Figure 14.16: bioAffinity Technologies, Inc.: Product Portfolio

Figure 14.17: bioAffinity Technologies, Inc.: SWOT Analysis

Figure 14.18: Bio-Rad Laboratories, Inc.: Product Portfolio

Figure 14.19: Bio-Rad Laboratories, Inc.: Overall Financials, 2018-2020

Figure 14.20: Bio-Rad Laboratories, Inc.: Revenue (by Segment), 2018-2020

Figure 14.21: Bio-Rad Laboratories, Inc.: Revenue (by Region), 2018-2020

Figure 14.22: Bio-Rad Laboratories, Inc.: R&D Expenditure, 2018-2020

Figure 14.23: Bio-Rad Laboratories, Inc.: SWOT Analysis

Figure 14.24: Bio-Techne Corporation: Product Portfolio

Figure 14.25: Bio-Techne Corporation: Overall Financials, 2018-2020

Figure 14.26: Bio-Techne Corporation: Revenue (by Segment), 2018-2020

Figure 14.27: Bio-Techne Corporation: Revenue (by Region), 2018-2020

- Figure 14.28: Bio-Techne Corporation: R&D Expenditure, 2018-2020
- Figure 14.29: Bio-Techne Corporation: SWOT Analysis
- Figure 14.30: Cytex Biosciences: Product Portfolio
- Figure 14.31: Cytex Biosciences: SWOT Analysis
- Figure 14.32: Cytognos, S.L.: Product Portfolio
- Figure 14.33: Cytognos, S.L.: SWOT Analysis
- Figure 14.34: Danaher Corporation: Product Portfolio
- Figure 14.35: Danaher Corporation: Overall Financials, 2018-2020
- Figure 14.36: Danaher Corporation: Revenue (by Segment), 2018-2020
- Figure 14.37: Danaher Corporation: Revenue (by Region), 2018-2020
- Figure 14.38: Danaher Corporation: R&D Expenditure, 2018-2020
- Figure 14.39: Danaher Corporation: SWOT Analysis
- Figure 14.40: Miltenyi Biotec B.V. & Co. KG: Product Portfolio
- Figure 14.41: Miltenyi Biotec B.V. & Co. KG: SWOT Analysis
- Figure 14.42: Laboratory Corporation of America Holdings: Service Portfolio
- Figure 14.43: Laboratory Corporation of America Holdings: Overall Financials, 2018-2020
- Figure 14.44: Laboratory Corporation of America Holdings: Revenue (by Segment), 2018-2020
- Figure 14.45: Laboratory Corporation of America Holdings: SWOT Analysis
- Figure 14.46: Luminex Corporation: Product Portfolio
- Figure 14.47: Luminex Corporation: Overall Financials, 2018-2020
- Figure 14.48: Luminex Corporation: Revenue (by Segment), 2018-2020
- Figure 14.49: Luminex Corporation: Revenue (by Region), 2018-2020
- Figure 14.50: Luminex Corporation: R&D Expenditure, 2018-2020
- Figure 14.51: Luminex Corporation: SWOT Analysis
- Figure 14.52: NeoGenomics Laboratories, Inc.: Service Portfolio
- Figure 14.53: NeoGenomics Laboratories, Inc.: Overall Financials, 2018-2020
- Figure 14.54: NeoGenomics Laboratories, Inc.: Revenue (by Segment), 2018-2020
- Figure 14.55: NeoGenomics Laboratories, Inc.: R&D Expenditure, 2018-2020
- Figure 14.56: NeoGenomics Laboratories, Inc.: SWOT Analysis
- Figure 14.57: Sony Corporation: Product Portfolio
- Figure 14.58: Sony Corporation: Overall Financials, 2018-2020
- Figure 14.59: Sony Corporation: Revenue (by Segment): 2018-2020
- Figure 14.60: Sony Corporation: Revenue (by Region), 2018-2020 (E)
- Figure 14.61: Sony Corporation: R&D Expenditure, 2018-2020 (E)
- Figure 14.62: Sony Corporation: SWOT Analysis
- Figure 14.63: Thermo Fisher Scientific, Inc.: Product Portfolio
- Figure 14.64: Thermo Fisher Scientific, Inc.: Overall Financials, 2018-2020

Figure 14.65: Thermo Fisher Scientific Inc.: Revenue (by Segment): 2018-2020

Figure 14.66: Thermo Fisher Scientific Inc.: Revenue (by Region), 2018-2020

Figure 14.67: Thermo Fisher Scientific Inc.: R&D Expenditure, 2018-2020

Figure 14.68: Thermo Fisher Scientific Inc.: SWOT Analysis

## I would like to order

Product name: Global Flow Cytometry in Oncology Market: Focus on Product Type, Technology, Type of Cancer, Applications, End Users, Country Data (16 Countries), and Competitive Landscape - Analysis and Forecast, 2021-2031

Product link: <https://marketpublishers.com/r/G13A9AFD9C5EEN.html>

Price: US\$ 5,250.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G13A9AFD9C5EEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below

and fax the completed form to +44 20 7900 3970